Comparison
Berberine vs TB-500
Side-by-side of Berberine and TB-500. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Berberine
Berberine supplement guide: 1500 mg/day lowers fasting glucose and HbA1c, AMPK activation, metformin parity in RCTs, dihydroberberine absorption.
TB-500
TB-500 peptide, a 17-aa thymosin beta-4 fragment. Preclinical tendon and wound healing via actin sequestration. Typical dosage 2 to 5 mg weekly. No human RCTs.
Effects at a glance
Berberine
- •Lowers HbA1c by ~0.7% versus placebo at 1500 mg/day across 27-trial meta-analysis (Lan 2015)
- •Roughly comparable to metformin on fasting glucose and HbA1c in small head-to-head RCTs (Yin 2008)
- •Reduces LDL cholesterol 10-20% and triglycerides 15-25% via PCSK9 inhibition
- •Activates AMPK, the cellular energy sensor that drives insulin-independent glucose uptake
- •Oral bioavailability under 1%; dihydroberberine is the higher-absorption alternative at lower doses
- •GI side effects affect 10-30% at 1500 mg/day; split dosing with meals reduces incidence
TB-500
- •17-amino-acid fragment of endogenous Thymosin Beta-4, an actin-sequestering peptide
- •Preclinical models show accelerated tendon, ligament, and dermal wound healing
- •Equine veterinary use for soft-tissue injury is the most documented real-world application
- •Anecdotal human protocols use 2 to 5 mg twice weekly subcutaneously for 4 to 6 weeks
- •WADA banned under S2 (peptide hormones, growth factors) since 2018
- •No completed phase II or III human RCTs as of 2026; long-term safety unestablished
Side-by-side
| Attribute | Berberine | TB-500 |
|---|---|---|
| Category | natural | peptide |
| Also known as | berberine HCl, berberine hydrochloride | Thymosin Beta-4 fragment, TB4-Frag, Thymosin Beta 4 |
| Half-life (hr) ↗ | 3 | 2 |
| Typical dose (mg) ↗ | 1500 | 2.5 |
| Dosing frequency | 3x daily with meals | 2x weekly (anecdotal protocols) |
| Routes | oral | subcutaneous, intramuscular |
| Onset (hr) | 2 | - |
| Peak (hr) | 3 | - |
| Molecular weight | 336.36 | 4963.4 |
| Molecular formula | C20H18NO4+ | C212H350N56O78S |
| Mechanism | Activates AMP-activated protein kinase (AMPK), suppressing hepatic gluconeogenesis and lipogenesis while increasing peripheral glucose uptake. Inhibits PCSK9 transcription, modulates bile acid signaling, and shifts gut microbiome composition. | Sequesters G-actin monomers, modulates cell migration and angiogenesis, and upregulates VEGF and myosin transcription. Promotes endothelial differentiation and stem-cell migration to injury sites in preclinical models. |
| Legal status | Dietary supplement (US, EU, UK, Canada); Rx in some Asian jurisdictions | Not FDA approved; research-use-only grey market; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Contraindicated (kernicterus risk in neonates) | Insufficient data |
| CAS | 2086-83-1 | 885340-08-9 |
| PubChem CID | 2353 | 62707662 |
| Wikidata | Q411435 | Q7799921 |
Safety profile
Berberine
Common side effects
- constipation
- diarrhea
- abdominal cramping
- flatulence
- nausea
Contraindications
- pregnancy
- lactation
- neonatal jaundice
- severe liver disease
Interactions
- metformin: additive HbA1c reduction; additive GI side effects(moderate)
- insulin or sulfonylureas: additive hypoglycemia risk; dose adjustment may be required(major)
- statins (simvastatin, atorvastatin): CYP3A4 inhibition raises statin plasma levels(moderate)
- cyclosporine: raises cyclosporine levels through CYP3A4 and P-gp inhibition(major)
- calcium channel blockers (amlodipine): elevated plasma levels via CYP3A4 inhibition(moderate)
TB-500
Common side effects
- injection-site irritation
- fatigue (anecdotal)
- lethargy in early dosing (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established human safety profile
Interactions
- BPC-157: Frequently co-administered in anecdotal healing protocols; no controlled interaction data(minor)
Which Should You Take?
Berberine comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. TB-500 is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Berberine.
- → If your priority is healthspan extension, pick Berberine.
- → If your priority is post-training recovery, pick TB-500.
- → If your priority is tendon repair, pick TB-500.
Edge case: If you want to avoid research-only / gray-market sourcing, Berberine is the more accessible choice.
Default choice: Berberine. Lower friction to source, and broader goal coverage. Reach for TB-500 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Berberine and TB-500?
Berberine and TB-500 differ in category (natural vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Berberine or TB-500?
Berberine half-life is 3 hours; TB-500 half-life is 2 hours.
Can you stack Berberine with TB-500?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper